Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
出版年份 2019 全文链接
标题
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 120, Issue 5, Pages 512-521
出版商
Springer Nature
发表日期
2019-02-15
DOI
10.1038/s41416-018-0373-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Breaking Kuhn's paradigm in advanced hepatocellular carcinoma
- (2018) David J. Pinato HEPATOLOGY
- Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
- (2018) Federica Fratangelo et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
- (2018) Luca Mologni et al. NEOPLASIA
- Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma
- (2017) Laure de Rosamel et al. EXPERT OPINION ON EMERGING DRUGS
- Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents
- (2017) Qiang Gao et al. GASTROENTEROLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
- (2017) David J. Pinato et al. OncoImmunology
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Gene of the month:Axl
- (2016) Matthew Brown et al. JOURNAL OF CLINICAL PATHOLOGY
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
- (2015) Naoshi Nishida et al. DIGESTIVE DISEASES
- Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
- (2015) Victoria Tovar et al. GUT
- Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma
- (2015) Patrick Reichl et al. HEPATOLOGY
- New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
- (2015) Makoto Chuma et al. HEPATOLOGY RESEARCH
- TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition
- (2015) D J Pinato et al. ONCOGENE
- Growth-Factor-Driven Rescue to Receptor Tyrosine Kinase (RTK) Inhibitors through Akt and Erk Phosphorylation in Pediatric Low Grade Astrocytoma and Ependymoma
- (2015) Mariska Sie et al. PLoS One
- Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma
- (2014) David J. Pinato et al. ADVANCES IN ANATOMIC PATHOLOGY
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- (2014) S. Trousil et al. CLINICAL CANCER RESEARCH
- Intratumor Heterogeneity in Hepatocellular Carcinoma
- (2014) J. Friemel et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
- (2014) C. Feneyrolles et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of intermediate-stage hepatocellular carcinoma
- (2014) Alejandro Forner et al. Nature Reviews Clinical Oncology
- Hepatoma SK Hep-1 Cells Exhibit Characteristics of Oncogenic Mesenchymal Stem Cells with Highly Metastatic Capacity
- (2014) Jong Ryeol Eun et al. PLoS One
- Current management of hepatocellular carcinoma
- (2014) Parissa Tabrizian WORLD JOURNAL OF GASTROENTEROLOGY
- Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
- (2013) M Kaliszczak et al. BRITISH JOURNAL OF CANCER
- A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
- (2013) M Kaliszczak et al. BRITISH JOURNAL OF CANCER
- An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
- (2013) Hsin-Jung Lee et al. CARCINOGENESIS
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
- (2013) Juliano D. Paccez et al. INTERNATIONAL JOURNAL OF CANCER
- The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma
- (2013) M A Cichoń et al. ONCOGENE
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
- (2012) Tokuzo Arao et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
- (2012) Marie-José Blivet-Van Eggelpoël et al. JOURNAL OF HEPATOLOGY
- Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
- (2012) David James Pinato et al. Journal of Thoracic Oncology
- Medical therapies for hepatocellular carcinoma: a critical view of the evidence
- (2012) Augusto Villanueva et al. Nature Reviews Gastroenterology & Hepatology
- The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
- (2011) Alvarez Hector et al. CANCER BIOLOGY & THERAPY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
- (2010) M Z Xu et al. ONCOGENE
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started